Swedish biotech chooses Recipharm for sepsis drug production

摘要

International CDMO Recipharm has partnered with biotechnology company Aptahem to formulate an injectable version of the drug candidate Apta-1.The aptamer-based drug candidate is intended to treat life-threatening sepsis,a potentially fatal condition that involves a general inflammatory response-known as systemic inflammatory response syndrome(SIRS)-caused by an infection.Recipharm will develop an injectable formulation for an upcoming Phase I study.Anders Hogdin,Senior Sales Director at Recipharm,said:”Recipharm has extensive experience in developing drugs for clinical trials,as well as in commercial manufacturing,and we believe that our team's expertise will be a very valuable asset during this new collaboration.”